Dealmaking Drives the Tape: These Stocks Are Heating Up into the Close

September 15, 2025

DENVER, Colo., Sep 15, 2025 (247marketnews.com)- Here are the tickers powering through power hour and the ones to watch in afterhours:

VENU (NYSE:VENU) shares are in the spotlight following its announcement of a multi-year exclusive ticketing and commerce partnership with Tixr, one of the fastest-growing live event ticketing platforms. Tixr also made a strategic equity investment, acquiring 62,500 shares of VENU stock via private placement.

The deal covers current and future VENU venues, including properties in Colorado Springs, Gainesville, Centennial, and one still-undisclosed metro. It comes on the heels of an earlier equity stake from Aramark (NYSE:ARMK), marking a rare dual endorsement from two major commercial partners.

This is a validation of VENU’s vertically integrated model, combining real estate, premium entertainment, and now tech-enabled ticketing. Tixr’s decision to invest suggests it sees upside not just as a vendor, but as a co-beneficiary of VENU’s growth trajectory.

With a small float and strategic capital coming in, *VENU is primed for fan epic short squeeze. Our most recent short squeeze ran from around $3.50 to $6.25 and may squeeze some more, but VENU has an even more epic setup.

Helius Medical Technologies (NASDAQ:HSDT) turned heads this morning, soaring on news of a $500 million+ private investment deal to launch SOL Treasury Company, a crypto treasury strategy focused on Solana (SOL).

Led by Pantera Capital and Summer Capital, with potential to scale to $1.25 billion through full warrant exercise, deal positions Helius as a public gateway for Solana-aligned DeFi strategy, mirroring how the MicroStrategy (NASDAQ:MSTR) became synonymous with Bitcoin.

Incoming executives from UBS, Pantera, and top crypto-native firms are reportedly being brought in to lead the transformation. The treasury will stake SOL to generate yield, creating a hybrid revenue engine at the intersection of healthcare tech and blockchain finance.

With crypto narratives gaining steam into Q4 and Solana outperforming majors, HSDT’s volume surge could continue after-hours, especially if crypto markets hold strong.

Monte Rosa Therapeutics (NASDAQ:GLUE) jumped in premarket trading and held gains throughout the session after inking a $120 million upfront licensing deal with Novartis (NYSE:NVS). The collaboration gives Novartis rights to use Monte Rosa’s targeted protein degraders for immune-mediated diseases, with additional milestone and royalty potential.

Monte Rosa’s proprietary QuEEN AI/ML drug discovery engine was a key factor in the deal, signaling big pharma’s confidence in AI-driven biotech platforms. The deal extends GLUE’s cash runway through multiple Phase 2 readouts and may pave the way for deeper partnership or M&A scenarios.

Institutional interest is expected to climb. GLUE is a top biotech breakout candidate into the close, especially with low-float dynamics and short interest potentially compounding gains.

InnSuites Hospitality Trust (NYSE:IHT) is quietly building a turnaround story. The company posted $4 million in revenue for the first half of FY2026 and set an all-time high $547,571 in hotel revenue for August alone. Its IBC Hotels platform is expanding its boutique brand focus.

Meanwhile, IHT’s diversification into clean energy via a stake in UniGen Power offers investors an upside lever tied to electricity grid modernization. Combined with a 55-year dividend streak, IHT is uniquely blending legacy yield with forward-looking innovation.

NanoVibronix (NASDAQ:NAOV) gained modest traction today after securing a new U.S. patent for its ENvue Medical subsidiary. The patent enhances its electromagnetic device placement technology used in enteral procedures, boosting safety and precision.

This is a key move for a microcap medical device company seeking to fortify its intellectual property in a high-acuity, low-competition niche. NAOV has long relied on tech defensibility and licensing potential, today’s news strengthens that positioning.

Spotlight Mentions:

  • Avita Medical’s (NASDAQ:RCEL): recent buzz around next-gen skin regeneration products may set up for further momentum gains.
  • Fastly (NYSE:FSLY) remains one to watch after last week’s AI edge compute expansion announcement.
  • LightPath Technologies (NASDAQ:LPTH) is still in play following recent DoD optics contract.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, HSDT, GLUE, IHT, NAOV, NVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.